Printer Friendly

ONCOR AND UNIVERSITY OF UTAH TO DEVELOP GENETIC TESTS FOR PROSTATE CANCER

 ONCOR AND UNIVERSITY OF UTAH TO DEVELOP GENETIC TESTS
 FOR PROSTATE CANCER
 GAITHERSBURG, Md., Aug. 25 /PRNewswire/ -- Oncor, Inc. (NASDAQ: ONCR), a leading manufacturer of DNA probe-based systems for the early detection and management of cancer and other genetic diseases, announced today that it has entered into a two-year agreement with the University of Utah, and the laboratory of Arthur R. Brothman, Ph.D., who will serve as the principal investigator.
 "This agreement is part of Oncor's 1992 program to build a strong set of relationships with leading clinical centers to advance the development and use of our DNA probe-based tests in oncology," commented George Evanega, Oncor's president and chief operating officer. "Prostate cancer is a particularly important target for Oncor, as its detection is currently difficult and prognosis is highly variable. Dr. Brothman is a leader in pioneering gene-based analysis of prostate cells, and we are very excited about working with him."
 Brothman stated, "Oncor's chromosome-specific DNA probes have already proven helpful in our preliminary studies and hold promise for providing a more accurate and rapid basis for identifying and grading prostate cancer cells. We look forward to working with Oncor to further characterize prostate carcinoma and develop clinical data toward allowing broad use for the detection and management of this disease."
 There are approximately 132,000 new cases of prostate cancer annually in the United States and in a male's lifetime the probability of having prostate cancer is one in 11. This is the most common cancer in men in the United States.
 Clinical studies will be conducted in 1992 and 1993 on the development of DNA probes for use in the detection and determining prognosis of prostate cancer. Oncor expects to use the results of the clinical studies to support FDA applications during the course of the agreement.
 -0- 8/25/92
 /CONTACT: Stephen Turner or George R. Evanega, Ph.D., 301-963-3500, both of Oncor/
 (ONCR) CO: Oncor, Inc.; University of Utah ST: Maryland, Utah IN: MTC SU:


GK-TM -- NY005 -- 2894 08/25/92 09:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 25, 1992
Words:340
Previous Article:DU PONT SCIENTISTS REPORT BREAKTHROUGH IN SUPERCONDUCTIVITY
Next Article:FIRST UNION SENDS BANKERS TO FLORIDA TO HELP WITH HURRICANE RELIEF EFFORTS
Topics:


Related Articles
ONCOR CONCLUDES PUBLIC OFFERING
ONCOR RECEIVES FDA MARKET APPROVAL ON SECOND GENERATION DNA-BASED TEST FOR DETECTION & MONITORING OF LEUKEMIA & LYMPHOMA
ONCOR, INCORPORATED ANNOUNCES EUROPEAN PARTNERSHIP WITH AMERSHAM INTERNATIONAL
ONCOR REPORTS RECORD SALES FOR FOURTH QUARTER AND FULL YEAR 1992
ONCOR REPORTS RECORD SALES FOR FIRST QUARTER 1993
ONCOR ACQUIRES EXCLUSIVE LICENSES FOR DNA PROBES TO DETECT THE TELOMERES OF HUMAN CHROMOSOMES
ONCOR LICENSES GENETIC TECHNOLOGY FOR THE EARLY DETECTION OF A COMMON TYPE OF COLON CANCER
ONCOR, INC.'S SUBSIDIARY, ONCORMED, INC., COMMENCES INITIAL PUBLIC OFFERING
ONCOR SUBMITS FDA APPLICATION FOR CHRONIC MYELOGENOUS LEUKEMIA GENETIC TEST SYSTEM
ONCOR ACQUIRES EXCLUSIVE LICENSE FROM JOHNS HOPKINS FOR CANCER SCREENING TEST

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters